This study revealed that olverembatinib, a novel multikinase inhibitor, has clinical activity in patients with advanced SDH-deficient GIST and has a manageable safety profile and durable response, with a median PFS of 25.7 months. Here, SDHB is linked to gastrointestinal stromal tumor.